Your diagnostic partner in Hemophilia
Versiti’s Factor VIII Chromogenic Activity (all-bovine reagent) is recommended for measuring endogenous or infused factor VIII activity and inhibitors, including the monitoring of patients with hemophilia A receiving emicizumab-kxwh (HEMLIBRA®). In addition, Versiti’s Factor VIII Inhibitor by chromogenic method is recommended to determine the presence of factor VIII inhibitor in patients with hemophilia A or acquired hemophilia, including patients receiving non-replacement products such as emicizumab-kxwh.
Advantages of Versiti's Factor VIII Chromogenic Assay:
Versiti’s Factor VIII Chromogenic Activity (all-bovine reagent) is can be used in the diagnosis of nonsevere hemophilia A, and useful in the accurate determination of factor VIII (FVIII) activity in the presence of a lupus anticoagulant or when certain modified recombinant FVIII replacement products are present, such as domain deleted Factor VIII formulations.